Study protocol: a multicentre, open-label, parallel-group, phase 2, randomised controlled trial of autologous macrophage therapy for liver cirrhosis (MATCH)
Paul Brennan(Ninewells Hospital), Stuart J. Forbes(MRC Centre for Regenerative Medicine), Neil McGowan(University of Aberdeen), Chloe Pass(Scottish National Blood Transfusion Service), Neil Lachlan(Glasgow Royal Infirmary), Alasdair R. Fraser(Scottish National Blood Transfusion Service), Scott Semple(University of Edinburgh), Mark T. Macmillan(MRC Centre for Regenerative Medicine), Francesca Moroni(Aberdeen Royal Infirmary), Catriona Graham(University of Edinburgh), Thomas Manship(NHS Lothian), Alison Glover(Scottish National Blood Transfusion Service), Jonathan Fallowfield(MRC Centre for Regenerative Medicine), Marc L. Turner(Scottish National Blood Transfusion Service), John Campbell(Institute of Infection and Immunity), David M. Morris(University of Edinburgh), John Dillon(University of Dundee)
Cited by 45
Related Papers
MAIT cells are activated during human viral infections
|Nature Communications|2016|520
Hepatic progenitor cells of biliary origin with liver repopulation capacity
|Nature Cell Biology|2015|500
Cell therapy for liver disease: From liver transplantation to cell factory
|Journal of Hepatology|2015|344
Liver regeneration and inflammation: from fundamental science to clinical applications
|Nature Reviews Molecular Cell Biology|2021|289
WNT signaling drives cholangiocarcinoma growth and can be pharmacologically inhibited
|Journal of Clinical Investigation|2015|274